Alzheimer's disease one century later: The search for effective therapeutic targets continues

Drugs of the Future

Volumn 32, Issue 7, 2007, Pages 625-641

  Sorbera, L A ^a   Bozzo, J ^a   Serradell, N ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA ESTRADIOL; ACETYLCHOLINESTERASE; AL 108; AMPA RECEPTOR; AMYLOID BETA PROTEIN; ANDROGEN RECEPTOR; AVE 1625; AVE 8112; AZD 103; AZD 3480; BAPINEUZUMAB; CALCIUM CHANNEL; CANNABINOID 1 RECEPTOR; CHOLINESTERASE; CR 3394; CURCUMIN; CX 717; DONEPEZIL; EHT 0202; ESTROGEN RECEPTOR; GALANTAMINE; GSK 189254; HE 0420; HOMOTAURINE; HUPERZINE A; IDEBENONE; INSULIN; ISPRONICLINE; LECOZOTAN; MEM 1003; MEM 1414; MEM 3454; MEMANTINE; MK 0952; NERAMEXANE; NGX 267; NGX 555; PAZ 417; PHENSERINE; PROSTAGLANDIN SYNTHASE; PRX 03140; RADEQUINIL; RASAGILINE; RIVASTIGMINE; ROSIGLITAZONE; SAM 315; TACRINE; TTP 488; UNCLASSIFIED DRUG; UNINDEXED DRUG; VP 4896; XALIPRODEN;

ALZHEIMER DISEASE; AMNESIA; BRAIN FUNCTION; CELL ADHESION; CELL MEMBRANE; CEREBROSPINAL FLUID; CLINICAL TRIAL; DISEASE COURSE; DRUG TARGETING; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HUMAN; NEUROFIBRILLARY TANGLE; OUTCOME ASSESSMENT; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 34548667909     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.07.1116862     Document Type: Review

References (154)

1. Prous Science Disease Briefings: Alzheimer's Disease (online publication). Updated 2007.
2. Aisen, P.S. The development of anti-amyloid therapy for Alzheimer's disease: From secretase modulators to polymerisation inhibitors. CNS Drugs 2005, 19(12): 989-96.
3. Zawia, N.H., Basha, M.R. Environmental risk factors and the developmental basis for Alzheimer's disease. Rev Neurosci 2005, 16(4): 325-37.
4. Marlatt, M.W., Webber, K.M., Moreira, P.I. et al. Therapeutic opportunities in Alzheimer disease: One for all or all for one? Curr Med Chem 2005, 12(10): 1137-47.
5. Roses, A.D., Saunders, A.M. Perspective on a pathogenesis and treatment of Alzheimer's disease. Alzheimer's & Dementia 2006, 2(2): 59-70.
6. Roberson, E.D., Mucke, L. 100 Years and counting: Prospects for defeating Alzheimer's disease. Science 2006, 314: 781-4.
7. Zimmermann, M., Gardoni, F., Di Luca, M. Molecular rationale for the pharmacological treatment of Alzheimer's disease. Drugs Aging 2005, 22(Suppl. 1): 27-37.
8. Sorbera, L.A., Castañer, J. Phenserine tartrate. Drugs Fut 2003, 28(1): 18-25.
9. Munoz-Torrero, D., Camps, P. Dimeric and hybrid anti-Alzheimer drug candidates. Curr Med Chem 2006, 13(4): 399-422.
10. Greig, N.H., Sambamurti, K., Yu, Q.S., Brossi, A. et al. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res 2005, 2(3): 281-90.
11. Nicoll, R.A., Tomita, S., Bredt, D.S. Auxiliary subunits assist AMPA-type glutamate receptors. Science 2006, 311(5765): 1253-6.
12. Black, M.D. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology (Berl) 2005, 179(1): 154-63.
13. Javitt, D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004, 9(11): 984-97.
14. Jacobsen, J.S., Reinhart. P., Pangalos, M.N. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. NeuroRx 2005, 2(4): 612-26.
15. Masters, C.L., Beyreuther, K. Alzheimer disease: Abeta-amyloid as the molecular therapeutic and diagnostic target. Neurobiol Aging [9th Int Geneva/Springfield Symp Adv Alzheimer Ther (April 19-22, Geneva) 2006] 2006, 27(Suppl. 1): Abst 57.
16. Saido, T.C. Metabolic regulation of amyloid, and Alzheimer disease. Neurobiol Aging [9th Int Geneva/Springfield Symp Adv Alzheimer Ther (April 19-22, Geneva) 2006] 2006, 27(Suppl. 1): Abst 74.
17. Lehmann, D.J., Butler, H.T., Warden, D.R. et al. Association of the androgen receptor CAG repeat polymorphism with Alzheimer's disease in men. Neurosci Lett 2003, 340(2): 87-90.
18. Carson, C.C. Effects of testosterone on cognition and mood in male patients with mild Alzheimer's disease and elderly men. Curr Urol Rep 2006, 7(6): 471-2.
19. Pike, C.J., Rosario, E.R., Nguyen, T.V. Androgens, aging, and Alzheimer's disease. Endocrine 2006, 29(2): 233-41.
20. Lu, P.H., Masterman, D.A., Mulnard, R. et al. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol 2006, 63(2): 177-85.
21. Ziora, Z., Kimura, T., Kiso, Y. Small-sized BACE1 inhibitors. Drugs Fut 2006, 31(1): 53-63.
22. Thompson, L.A., Bronson, J.J., Zusi, F.C. Progress in the discovery of BACE inhibitors. Curr Pharm Des 2005, 11(26): 3383-404.
23. Cumming, J.N., Iserloh, U., Kennedy, M.E. Design and development of BACE-1 inhibitors. Curr Opin Drug Discov Devel 2004, 7(4): 536-56.
24. Small, G.W., Kaufer, D., Mendiondo, M.S. et al. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 2005, 59(4): 473-7.
25. Ballard, C.G., Greig, N.H., Guillozet-Bongaarts, A.L. et al. Cholinesterases: Roles in the brain during health and disease. Curr Alzheimer Res 2005, 2(3): 307-18.
26. Geula, C., Darvesh, S. Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer's disease. Drugs Today (Barc) 2004, 40(8): 711-21.
27. Wenk, G.L. Neuropathologic changes in Alzheimer's disease: Potential targets for treatment. J Clin Psychiatry 2006, 67(Suppl. 3): 3-7.
28. Ma, Z.G., Wang, J., Jiang, H., Xie, J.X., Chen, L. C31 enhances voltage-gated calcium channel currents in undifferentiated PC12 cells. Neurosci Lett 2005, 382(1-2): 102-5.
29. Schmitt, H.P. On the paradox of ion channel blockade and its benefits in the treatment of Alzheimer disease. Med Hypotheses 2005, 65(2): 259-65.
30. Nagayama, T., Sinor, A.D., Simon, R.P. et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999, 19(8): 2987-95.
31. Ramirez, B.G., Blazquez, C., Gomez del Pulgar, T., Guzman, M., de Ceballos, M.L. Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J Neurosci 2005, 25(8): 1904-13.
32. Pazos, M.R., Nunez, E., Benito, C., Tolon, R.M., Romero, J. Role of the endocannabinoid system in Alzheimer's disease: New perspectives. Life Sci 2004, 75(16): 1907-15.
33. Benito, C., Nunez, E., Tolon, R.M., Carrier, E.J., Rábano, A., Hillard, C.J., Romero, J. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 2003, 23(35): 11136-41.
34. Guo, Q. When good Cdk5 turns bad. Sci Aging Knowledge Environ 2006, 2006(5): pe5.
35. Giese, K.P., Ris, L., Plattner, F. Is there a role of the cyclin-dependent kinase 5 activator p25 in Alzheimer's disease? Neuroreport 2005, 16(16): 1725-30.
36. Duff, K., Planet, E., Krishnamurthy, P., Wen, Y. Impact of kinase modulation on pathogenesis in mouse models of neurodegenerative disease. Neurobiol Aging [9th Int Geneva/Springfield Symp Adv Alzheimer Ther (April 19-22, Geneva) 2006] 2006, 27(Suppl. 1): Abst 24.
37. Patrick, G.N., Zukerberg, L., Nikolic, M. et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999, 402: 615-22.
38. Firuzi, O., Pratico, D. Coxibs and Alzheimer's disease: Should they stay or should they go? Ann Neurol 2006, 59(2): 219-28.
39. Ho, L., Qin, W., Stetka, B.S., Pasinetti, G.M. Is there a future for cyclo-oxygenase inhibitors in Alzheimer's disease? CNS Drugs 2006, 20(2): 85-98.
40. Lanari, A., Amenta, F., Silvestrelli, G., Tomassoni, D., Pametti, L. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. Mech Ageing Dev 2006, 127(2): 158-65.
41. Mateo, I., Infante, J., Rodriguez, E., Berciano, J., Combarros, O., Llorca, J. Interaction between dopamine beta-hydroxylase and interleukin genes increases Alzheimer's disease risk. J Neurol Neurosurg Psychiatry 2006, 77(2): 278-9.
42. Uzun, S., Kozumplik, O., Mimica, N., Folnegovic-Smalc, V. Aripiprazole: An overview of a novel antipsychotic. Psychiatr Danub 2005, 17(1-2): 67-75.
43. Yaffe, K., Krueger, K., Cummings, S.R. et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: The Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 2005, 162(4): 683-90.
44. Baum, L.W. Sex, hormones, and Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2005, 60(6): 736-43.
45. Zhao, L., Brinton, R.D. Select estrogens within the complex formulation of conjugated equine estrogens (Premarin) are protective against neurodegenerative insults: Implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer's disease. BMC Neurosci 2006, 7: 24.
46. Pirskanen, M., Hiltunen, M., Mannermaa, A., Helisalmi, S., Lehtovirta, M., Hanninen, T., Sorininen, H. Estrogen receptor beta gene variants are associated with increased risk of Alzheimer's disease in women. Eur J Hum Genet 2005, 13(9): 1000-6.
47. Ohmichi, M., Tasaka, K., Kurachi, H., Murata, Y. Molecular mechanism of action of selective estrogen receptor modulator in target tissues. Endocr J 2005, 52(2): 161-7.
48. Dhandapani, K.M., Brann, D.W. Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol Reprod 2002, 67(5): 1379-85.
49. Osterlund, M.K., Gustafsson, J.A., Keller, E., Hurd, Y.L. Estrogen receptor beta (ERbeta) messenger ribonucleic acid (mRNA) expression within the human forebrain: Distinct distribution pattern to ERalpha mRNA. J Clin Endocrinol Metab 2000, 85(10): 3840-6.
50. Moreira, P.I., Honda, K., Zhu, X. et al. Brain and brawn: Parallels in oxidative strength. Neurology 2006, 66(2, Suppl. 1): S97-101.
51. Frank, B., Gupta, S. A review of antioxidants and Alzheimer's disease. Ann Clin Psychiatry 2005, 17(4): 269-86.
52. Liu, R., Liu, I.Y., Bi, X., Thompson, R.F., Doctrow, S.R., Malfroy, B., Baudry, M. Reversal of age-related learning deficits and brain oxidative stress in mice with superoxide dismutase/catalase mimetics. Proc Natl Acad Sci USA 2003, 100(14): 8526-31.
53. Kontush, K., Schekatolina, S. Vitamin E in neurodegenerative disorders: Alzheimer's disease. Ann NY Acad Sci 2004, 1031: 249-62.
54. Rosato-Siri, M., Cattaneo, A., Cherubini, E. Nicotine-induced enhancement of synaptic plasticity at CA3-CA1 synapses requires GABAergic interneurons in adult anti-NGF mice. J Physiol 2006, 576(Pt. 2): 361-77.
55. Lanctot, K.L., Herrmann, N., Mazzotta, P., Khan, L.R., Ingber, N. GABAergic function in Alzheimer's disease: Evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J Psychiatry 2004, 49(7): 439-53.
56. Schmitt, H.P. Neuro-modulation, aminergic neuro-disinhibition and neuro-degeneration. Draft of a comprehensive theory for Alzheimer disease. Med Hypotheses 2005, 65(6): 1106-19.
57. Twomey, C., McCarthy, J.V. Presenilin-1 is an unprimed glycogen synthase kinase-3beta substrate. FEBS Lett 2006, 580(17): 4015-20.
58. Bhat, R., Berg, S. Role of GSK3 in Alzheimer disease. Neurobiol Aging [9th Int Geneva/Springfield Symp Adv Alzheimer Ther (April 19-22, Geneva) 2006] 2006, 27(Suppl. 1): Abst 9.
59. Jiang, H., Guo, W., Liang, X., Rao, Y. Both the establishment and the maintenance of neuronal polarity require active mechanisms: Critical roles of GSK-3beta and its upstream regulators. Cell 2005, 120: 123-35.
60. Conde, S., Perez, D.I., Martinez, A., Perez, C., Moreno, F.J. Thienyl and phenyl alpha-halomethyl ketones: New inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching. J Med Chem 2003, 46(22): 4631-3.
61. Kuo, G.-H., Prouty, C., De Angelis, A. et al. Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors. J Med Chem 2003, 46(19): 4021-31.
62. Hoeflich, K.P., Luo, J., Rubie, E.A, Tsao, M.S., Jin, O., Woodgett, J.R. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000, 406(6791): 86-90.
63. Casadesus, G., Webber, K.M., Atwood, C.S., Pappolla, M.A., Perry, G., Bowen, R.L., Smith, M.A. Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice. Biochim Biophys Acta 2006, 1762(4): 447-52.
64. Rosin, R.A., Raskind, M.A. Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: A case report. Int Psychogeriatr 2005, 17(2): 313-8.
65. Meethal, S.V., Smith, M.A., Bowen, R.L., Atwood, C.S. The gonadotropin connection in Alzheimer's disease. Endocrine 2005, 26(3): 317-26.
66. Veereshwarayya, V., Kumar, P., Rosen, K.M., Mestril, R., Quenfurth, H.W. Differential effects of mitochondrial heat shock protein 60 and related molecular chaperones to prevent intracellular beta-amyloid-induced inhibition of complex IV and limit apoptosis. J Biol Chem 2006, 281(46): 29468-78.
67. Evans, C.G., Wisen, S., Gestwicki, J.E. Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. J Biol Chem 2006, 281(44): 33182-91.
68. Sahara, N., Murayama, M., Mizoroki, T. et al. In vivo evidence of CHIP up-regulation attenuating tau aggregation. J Neurochem 2005, 94(5): 1254-63.
69. Petrucelli, L., Dickson, D., Kehoe, K. et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 2004, 13(7): 703-14.
70. Hamos, J.E., Oblas, B., Pulaski-Salo, D., Welch, W.J., Bole, D.G., Drachman, D.A. Expression of heat shock proteins in Alzheimer's disease. Neurology 1991, 41: 345-50.
71. Perez, N., Sugar, J., Charya, S. et al. Increased synthesis and accumulation of heat shock 70 proteins in Alzheimer's disease. Brain Res Mol Brain Res 1991, 11(3-4): 249-54.
72. Passani, M.B., Lin, J.S., Hancock, A., Crochet, S., Blandina, P. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 2004, 25(12): 618-25.
73. Ohm, T.G., Meske, V. Cholesterol, statins and tau. Acta Neurol Scand Suppl 2006, 185: 93-101.
74. Tang, B.L. Alzheimer's disease: Channeling APP to non-amyloidogenic processing. Biochem Biophys Res Commun 2005, 331(4): 375-8.
75. DeKosky, S.T. Statin therapy in the treatment of Alzheimer disease: What is the rationale? Am J Med 2005, 118(Suppl. 12A): 48-53.
76. Ohm, T.G. et al. Cholesterol and tau protein -Findings in Alzheimer's and Niemann Pick C's disease. Pharmacopsychiatry 2003, 36(Suppl. 2): S120-6.
77. Kirsch, C. et al. Brain cholesterol, statins and Alzheimer's disease. Pharmacopsychiatry 2003, 36(Suppl. 2): S113-9.
78. Revill, P., Moral, M.A., Prous, J.R. Impaired insulin signaling and the pathogenesis of Alzheimer's disease. Drugs Today (Bare) 2006, 42(12): 785-90.
79. Sun, M.K., Alkon, D.L. Links between Alzheimer's disease and diabetes. Drugs Today (Barc) 2006, 42(7): 481-9.
80. Rivera, E.J., Goldin, A., Fulmer, N., Tavares, R., Doiron, K., Wands, J.R., de la Monte, S.M. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: Link to brain reductions in acetylcholine. J Alzheimers Dis 2005, 8(3): 247-68.
81. Schubert, M., Gautam, D., Surjo, D. et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci USA 2004, 101(9): 3100-5.
82. D'Ambrosio, C., Arena, S., Fulcoli, G., Scheinfeld, M.H., Zhou, D., D'Adamio, L., Scaloni, A. Hyperphosphorylation of JNK-interacting protein 1, a protein associated with Alzheimer disease. Mol Cell Proteomics 2006, 5(1): 97-113.
83. Ferrer, I., Gomez-Isla, T., Puig, B., Freixes, M., Ribé, E., Dalfo, E., Avila, J. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2005, 2(1): 3-18.
84. Kuan, C.Y., Burke, R.E. Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy. Curr Drug Targets CNS Neurol Disord 2005, 4(1): 63-7.
85. Ucar, G., Gokhan, N., Yesilada, A., Bilgin, A.A. 1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: A novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases. Neurosci Lett 2005, 382(3): 327-31.
86. Youdim, M.B., Fridkin, M., Zheng, H. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev 2005, 126(2): 317-26.
87. Chen, K., Holschneider, D.P., Wu, W., Rebrin, I., Shih, J.C. A spontaneous point mutation produces monoamine oxidase A/B knock-out mice with greatly elevated monoamines and anxiety-like behavior. J Biol Chem 2004, 279(38): 39645-52.
88. Clader, J.W., Wang, Y. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease. Curr Pharm Des 2005, 11(26): 3353-61.
89. Verhoeff, N.P. Acetylcholinergic neurotransmission and the beta-amyloid cascade: implications for Alzheimer's disease. Expert Rev Neurother 2005, 5(2): 277-84.
90. Fisher, A., Caccamo, A., Oddo, S. et al. M1 muscarinic agonists as promising agents to decrease beta-amyloids in Alzheimer disease (AD) brains. Neurobiol Aging [9th Int Geneva/Springfield Symp Adv Alzheimer Ther (April 19-22, Geneva) 2006] 2006, 27(Suppl. 1): Abst 30.
91. Lambiase, A., Pagani, L., Di Fausto, V., Sposato, V., Coassin, M., Bonini, S., Aloe, L. Nerve growth factor eye drop administrated on the ocular surface of rodents affects the nucleus basalis and septum: Biochemical and structural evidence. Brain Res 2007, 1127(1): 45-51.
92. Counts, S.E., Mufson, E.J. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J Neuropathol Exp Neurol 2005, 64(4): 263-72.
93. Volosin, M., Song, W., Almeida, R.D., Kaplan, D.R., Hempstead, B.L., Friedman, W.I. Interaction of survival and death signaling in basal forebrain neurons: Roles of neurotrophins and proneurotrophins. J Neurosci 2006, 26(29): 7756-66.
94. Tuszynski, M.H., Thai, L., Pay, M. et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005, 11(5): 551-5.
95. Secher, T., Novitskaia, V., Berezin, V., Bock, E., Glenthoj, B., Klementiev, B. A neural cell adhesion molecule-derived fibroblast growth factor receptor agonist, the FGL-peptide, promotes early postnatal sensorimotor development and enhances social memory retention. Neuroscience 2006, 141(3): 1289-99.
96. Strekalova, H., Buhmann, C., Kleene, R. et al. Elevated levels of neural recognition molecule L1 in the cerebrospinal fluid of patients with Alzheimer disease and other dementia syndromes. Neurobiol Aging 2006, 27(1): 1-9.
97. Todaro, L., Puricelli, L., Gioseffi, H. et al. Neural cell adhesion molecule in human serum. Increased levels in dementia of the Alzheimer type. Neurobiol Dis 2004, 15(2): 387-93.
98. Berezin, V., Bock, E. NCAM mimetic peptides: Pharmacological and therapeutic potential. J Mol Neurosci 2004, 22(1-2): 33-9.
99. D'Andrea, M.R., Nagele, R.G. Targeting the alpha 7 nicotinic ACh receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons. Curr Pharm Des 2006, 12(6): 677-84.
100. Magdesian, M.H., Nery, A.A., Martins, A.H., Juliano, M.A., Juliano, L., Ulrich, H., Ferreira, S.T. Peptide blockers of the inhibition of neuronal nicotinic ACh receptors by amyloid beta. J Biol Chem 2005, 280(35): 31085-90.
101. Vignini, A., Nanetti, L., Moroni, C. et al. Modifications of platelet from Alzheimer disease patients: A possible relation between membrane properties and NO metabolites. Neurobiol Aging 2007, 28(7): 987-94.
102. Akomolafe, A., Lunetta, K.L., Erlich, P.M. et al. Genetic association between endothelial nitric oxide synthase and Alzheimer disease. Clin Genet 2006, 70(1): 49-56.
103. Thatcher, G.R., Bennett, B.M., Reynolds, J.N. Nitric oxide mimetic molecules as therapeutic agents in Alzheimer's disease. Curr Alzheimer Res 2005, 2(2): 171-82.
104. Riederer, P., Hoyer, S. From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain. J Neural Transm 2006, 113(11): 1671-7.
105. Snyder, E.M., Nong, Y., Almeida, C.G. et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005, 8(8): 1051-8.
106. Narahashi, T., Marszalec, W., Moriguchi, S., Yeh, J.Z., Zhao, X. Unique mechanism of action of Alzheimer's drugs on brain nicotinic ACh receptors and NMDA receptors. Life Sci 2003, 74(2-3): 281-91.
107. Lleo, A., Greenberg, S.M., Growdon, J.H. Current pharmacotherapy for Alzheimer's disease. Annu Rev Med 2006, 57: 513-33.
108. Francis, P.T. The interplay of neurotransmitters in Alzheimer's disease. CNS Spectr 2005, 10(11, Suppl. 18): 6-9.
109. Townsend, K.P., Pratico, D. Novel therapeutic opportunities for Alzheimer's disease: Focus on nonsteroidal anti-inflammatory drugs. FASEB J 2005, 19(12): 1592-601.
110. Chen, J., Zhou, Y., Mueller-Steiner, S. et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005, 280(48): 40364-74.
111. Onyango, I.G., Tuttle, J.B., Bennett, J.P. Jr. Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE). Mol Cell Neurosci 2005, 29(2): 333-43.
112. Sastre, M., Dewachter, I., Rossner, S. et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci USA 2006, 103(2): 443-8.
113. Watson, G.S., Cholerton, B.A., Reger, M.A. et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study. Am J Geriatr Psychiatry 2005, 13: 950-8.
114. d'Abramo, C., Massone, S., Zingg, J.M. et al. Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochem J 2005, 391 (Pt. 3): 693-8.
115. Ghavami, A., Hirst, W.D., Novak, T.J. Selective phosphodiesterase (PDE)-4 inhibitors: A novel approach to treating memory deficit? Drugs R D 2006, 7(2): 63-71.
116. Beglopoulos, V., Shen, J. Regulation of CRE-dependent transcription by presenilis: Prospects for therapy of Alzheimer's disease. Trends Pharmacol Sci 2006, 27(1): 33-40.
117. Houslay, M.D., Schafer, P., Zhang, K.Y. Keynote review: Phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005, 10(22): 1503-19.
118. Zhang, L., Zhang, R.L., Wang, Y., Zhang, C., Zhang, Z.G., Meng, H., Chopp, M. Functional recovery in aged and young rats after embolic stroke: Treatment with a phosphodiesterase type 5 inhibitor. Stroke 2005, 36(4): 847-52.
119. Devan, B.D., Duffy, K.B., Bowker, J.L. et al. Phosphodiesterase type 5 (PDE5) inhibition and cognitive enhancement. Drugs Fut 2005, 30(7): 725-36.
120. Zhu, D., Lai, Y., Shelat, P.B., Hu, C., Sun, G.Y., Lee, J.C. Phospholipases A2 mediate amyloid-beta peptide-induced mitochondrial dysfunction. J Neurosci 2006, 26(43): 11111-9.
121. Zhu, X., Smith, M.A. Perry, G., Aliev, G. Mitochondrial failures in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2004, 19(6): 345-52.
122. Caspersen, C., Wang, N., Yao, J. et al. Mitochondrial Abeta: A potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 2005, 19(14): 2040-1.
123. Pastorino, L., Lu, K.P. Pathogenic mechanisms in Alzheimer's disease. Eur J Pharmacol 2006, 545(1): 29-38.
124. Pastorino, L., Sun, A., Lu, P.J et al. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 2006, 440: 528-34.
125. Lim, J., Lu, K.P. Pinning down phosphorylated tau and tauopathies. Biochim Biophys Acta 2005, 1739(2-3): 311-22.
126. Wulf, G., Finn, G., Suizu, F., Lu, K.P. Phosphorylation-specific prolyl isomerization: Is there an underlying theme? Nat Cell Biol 2005, 7(5): 435-41.
127. Liou, Y.C., Sun, A., Ryo, A. et al. Role of the prolyl isomerase Pint in protecting against age-dependent neurodegeneration. Nature 2003, 424: 556-61.
128. Ledesma, M.D., Abad-Rodriguez, J., Galvan, C. et al. Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains. EMBO Rep 2003, 4(12): 1190-6.
129. Ledesma, M.D., Da Silva, J.S., Crassaerts, K., Delacourte, A., De Strooper, B., Dotti, C.G. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep 2000, 1(6): 530-5.
130. Dotti, C.G., Galvan, C., Ledesma, M.D. Plasmin deficiency in Alzheimer's disease brains: Causal or casual? Neurodegener Dis 2004, 1(4-5): 205-12.
131. Melchor, J.P., Pawlak, R., Strickland, S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci 2003, 23(26): 8867-71.
132. Ozturk, A., Minster, R.L., DeKosky, S.T., Kamboh, M.I. Association of tagSNPs in the urokinase-plasminogen activator (PLAU) gene with Alzheimer's disease and associated quantitative traits. Am J Med Genet B Neuropsychiatr Genet 2007, 144(1): 79-82.
133. Riemenschneider, M., Konta, L., Friedrich, P. et al. A functional polymorphism within plasminogen activator urokinase (PLAU) is associated with Alzheimer's disease. Hum Mol Genet 2006, 15(16): 2446-56.
134. Medina, M.G., Ledesma, M.D., Dominguez, J.E. et al. Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation. EMBO J 2005, 24(9): 1706-16.
135. Schmitt, H.P. epsilon-Glycation, APP and Abeta in ageing and Alzheimer disease: A hypothesis. Med Hypotheses 2006, 66(5): 898-906.
136. Emanuele, E., D'Angelo, A., Tomaino, C. et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 2005, 62(11): 1734-6.
137. Alarcon, R. Fuenzalida, C., Santibanez, M., von Bernhardi, R. Expression of scavenger receptors in glial cells. Comparing the adhesion of astrocytes and microglia from neonatal rats to surface-bound beta-amyloid. J Biol Chem 2005, 280(34): 30406-15.
138. Tomita, T., Iwatsubo, T. gamma-Secretase as a therapeutic target for treatment of Alzheimer's disease. Curr Pharm Des 2006, 12(6): 661-70.
139. Churcher, I., Beher, D. Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease. Curr Pharm Des 2005, 11(26): 3363-82.
140. Kojro, E., Fahrenholz, F. The non-amyloidogenic pathway: Structure and function of alpha-secretases. Subcell Biochem 2005, 38: 105-27.
141. Chang, W., Huang, X., Koelsch, G., Hong, L., Ghosh, K.A., Tang, J. Beta-secretase inhibitor drug, between fantasy and reality. Neurobiol Aging [9th Int Geneva/Springfield Symp Adv Alzheimer Ther (April 19-22, Geneva) 2006] 2006, 27(Suppl. 1): Abst 87.
142. Fahrenholz, F. Alpha-secretase as a therapeutic target. Neurobiol Aging [9th Int Geneva/Springfield Symp Adv Alzheimer Ther (April 19-22, Geneva) 2006] 2006, 27(Suppl. 1): Abst 27.
143. Bandyopadhyay, S., Hartley, D.M., Cahill, C.M., Lahiri, D.K., Chattopadhyay, N., Rogers, J.T. Interleukin-1 alpha stimulates non-amyloidogenic pathway by alpha-secretase (ADAM-10 and ADAM-17) cleavage of APP in human astrocytic cells involving p38 MAP kinase. J Neurosci Res 2006, 84(1): 106-18.
144. Lichtenthaler, S.F., Haass, C. Amyloid at the cutting edge: Activation of alpha-secretase prevents amyloidogenesis in an Alzheimer disease mouse model. J Clin Invest 2004, 113(10): 1384-7.
145. Vincent, B. ADAM proteases: Protective role in Alzheimer's and prion diseases? Curr Alzheimer Res 2004, 1(3): 165-74.
146. Allinson, T.M., Parkin, E.T., Turner, A.J., Hooper, N.M. ADAMs family members as amyloid precursor protein alpha-secretases. J Neurosci Res 2003, 74(3): 342-52.
147. Asai, M., Hattori, C., Szabo, B., Sasagawa, N., Maruyama, K., Tanuma, S., Ishiura, S.. Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. Biochem Biophys Res Commun 2003, 301(1): 231-5.
148. Zarros, A.Ch., Kalopita, K.S., Tsakiris, S.T. Serotoninergic impairment and aggressive behavior in Alzheimer's disease. Acta Neurobiol Exp (Wars) 2005, 65(3): 277-86.
149. Mitchell, E.S., Neumaier, J.F. 5-HT6 receptors: A novel target for cognitive enhancement. Pharmacol Ther 2005, 108(3): 320-33.
150. Cho, S., Hu, Y. Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. Exp Neurol 2007, 203(1): 274-8.
151. Tesseur, I., Zou, K., Esposito, L. et al. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J Clin Invest 2006, 116(11): 3060-9.
152. Buckwalter, M.S., Coleman, B.S., Buttini, M. et al. Increased T cell recruitment to the CNS after amyloid beta 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-beta 1. J Neurosci 2006, 26(44): 11437-41.
153. Zhang, H., Zou, K., Tesseur, I., Wyss-Coray, T. Small molecule TGF-beta mimetics as potential neuroprotective factors. Curr Alzheimer Res 2005, 2(2): 183-6.
154. Wyss-Coray, T. TGF-beta pathway as a potential target in neurodegeneration and Alzheimer's. Curr Alzheimer Res 2006, 3(3): 191-5.